Literature DB >> 9552053

Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.

R Gorlick1, R Metzger, K D Danenberg, D Salonga, J S Miles, G S Longo, J Fu, D Banerjee, D Klimstra, S Jhanwar, P V Danenberg, N Kemeny, J R Bertino.   

Abstract

PURPOSE: It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local). To investigate the basis of this chemoresistance, the levels of thymidylate synthase (TS) mRNA and protein were measured, as TS expression has been shown to be predictive of response to therapy in colorectal cancer.
MATERIALS AND METHODS: Tumors were obtained from 19 patients with metastatic colorectal cancer (12 hepatic and seven pulmonary). TS expression was measured by quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) and TS protein levels were measured by Western blotting. The presence of TS amplification was assessed by Southern blotting. Levels of p53 protein were determined using immunohistochemistry.
RESULTS: TS mRNA expression was shown to be significantly higher in the pulmonary metastases (mean TS/beta-actin ratio, 19.7; n = 7) as compared with the hepatic metastases (mean TS/beta-actin ratio, 4.7; n = 11) of colorectal cancer. Lower TS expression was observed in patients with hepatic metastases who had received prior FUra versus patients who had not been treated. High levels of TS expression in some samples was associated with low-level (two to three gene copies) increases in TS gene copy numbers and this was observed more frequently in the pulmonary metastatic samples. The increased gene copy numbers occurred both in samples with wild-type p53 and those with mutant p53 tumor-suppressor gene as determined by immunohistochemistry.
CONCLUSION: High levels of TS enzyme may be the basis of the lack of response of pulmonary metastases to FUra treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9552053     DOI: 10.1200/JCO.1998.16.4.1465

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

2.  Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase.

Authors:  Maria Marjorette O Peña; Yang Yang Xing; Sangita Koli; Franklin G Berger
Journal:  Biochem J       Date:  2006-02-15       Impact factor: 3.857

Review 3.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 4.  Emerging personalized approaches for the management of advanced urothelial carcinoma.

Authors:  Che-Kai Tsao; Benjamin A Gartrell; William K Oh; Matthew D Galsky
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

5.  Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy.

Authors:  Myung-Ju Ahn; Jung-Hye Choi; Ho-Suk Oh; Young-Yeul Lee; In-Soon Kim; Il-Young Choi; Kang-Hong Lee; Kang-Won Song; Chan-Kum Park
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

6.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

Review 7.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

Review 8.  Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.

Authors:  Andrea Formentini; Doris Henne-Bruns; Marko Kornmann
Journal:  Langenbecks Arch Surg       Date:  2004-08-12       Impact factor: 3.445

9.  Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.

Authors:  L Assersohn; A Norman; D Cunningham; T Benepal; P J Ross; J Oates
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer.

Authors:  Qiong Hu; Xuefei Li; Chunxia Su; Xiaoxia Chen; Guanghui Gao; Jie Zhang; Yinmin Zhao; Jiayu Li; Caicun Zhou
Journal:  Exp Ther Med       Date:  2012-09-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.